The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Shikh E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Rebrova E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ryazanova A.Y.

Volgograd State Medical University

Arzhimatova G.Sh.

Russian Medical Academy of Continuing Professional Education;
S.P. Botkin City Clinical Hospital

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Drug-induced toxic optic neuropathy

Authors:

Ostroumova O.D., Shikh E.V., Rebrova E.V., Ryazanova A.Y., Arzhimatova G.Sh., Moshetova L.K.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(4): 156‑164

DOI: 10.17116/oftalma2020136041156

Read: 13840 times

Download PDF (RU)
Contact the author
Table of contents

DRUG-INDUCED TOXIC OPTIC NEUROPATHY
DRUG-INDUCED TOXIC OPTIC NEUROPATHY

To cite this article:

Ostroumova OD, Shikh EV, Rebrova EV, Ryazanova AY, Arzhimatova GSh, Moshetova LK. Drug-induced toxic optic neuropathy. Russian Annals of Ophthalmology. 2020;136(4):156‑164. (In Russ.)
https://doi.org/10.17116/oftalma2020136041156

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Drug-induced optic neuropathy is a group of disorders in which medications cause degeneration of the optic nerve. The true prevalence of drug-induced neuropathy has not been studied, although the percentage of patients who develop optic nerve damage is known for individual medications. The common pathophysiological mechanisms are believed to be mitochondrial damage and imbalance of intracellular and extracellular free radical homeostasis. Typical symptoms of drug-induced neuropathy are reduced visual acuity in the central area, which is often bilateral, visual field disturbances, dyschromatopsia, and edema of the optic nerve head. Early detection of drug-induced optic neuropathy can potentially prevent or minimize serious complications. For patients who develop drug-induced optic neuropathy, treatment is based on timely diagnosis and cancellation of the provoking drug. In most patients, vision usually recovers a few weeks or months after discontinuation of previous therapy, but there have been cases of irreversible vision loss. In addition to withdrawal of the drug that caused optic nerve lesion, treatment of drug-induced neuropathy may include use of drugs and treatment methods prescribed by neurologists for peripheral neuropathy, however, such treatment is seldom based on evidence.

Keywords:

drug-induced optic neuropathy
ethambutol
amiodarone-associated optic neuropathy
adverse drug reactions
optic nerve

Authors:

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Shikh E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Rebrova E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ryazanova A.Y.

Volgograd State Medical University

Arzhimatova G.Sh.

Russian Medical Academy of Continuing Professional Education;
S.P. Botkin City Clinical Hospital

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Received:

02.06.2020

Accepted:

08.06.2020

Close metadata

References:

  1. Constable S, Pirmohamed M. Drugs and the retina. Expert Opin Drug Saf. 2004;3(3):249-259.  https://doi.org/10.1517/eods.3.3.249.31070
  2. Phillips PH. Toxic and deficiency opticneuropathies. In: Miller N.R., Newman N.J., Biousse V., Kerrison J.B. Walsh and Hoyt’s clinical neuroophthalmology. 6th ed. Baltimore, MD: Lippincott Williamsand Wilkins; 2005.
  3. Grzybowski A, Zülsdorff M, Wilhelm H, Tonagel F. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402-410.  https://doi.org/10.1111/aos.12515
  4. Ophthalmology. National guideline. Eds Avetisova S.E., Egorova E.A., Moshetova L.K., Neroeva V.V., Tahchidi H.P. M.: GEOTAR-Media; 2011. (In Russ.).
  5. Ambizas EM, Patel PN. Drug-Induced Optic Neuropathy. US Pharm. 2011; 36(4):2-6. 
  6. Lloyd MJ, Fraunfelder FW. Drug-induced optic neuropathies. Drugs Today (Barc). 2007;43(11):827-836.  https://doi.org/10.1358/dot.2007.43.11.1157621
  7. Reeks GA, Ang GS. Follow-up of suspected ocular adverse drug reactions. Acta Ophthalmol. 2010;88:79-80.  https://doi.org/10.1111/j.1755-3768.2009.01720.x
  8. Drugs.com. Prescription Drug Information, Interactioms, Side Effects. Accessed 05.05.20.  https://www.drugs.com
  9. Sheremet NL, Andreeva NA, Meshkov AD, Chukhrova AL, Loginova AN, Polyakov AV. The ecological structure of non-glaucoma optical neuropathies. Sibirskiy nauchnyy meditsinskiy zhurnal. 2018;38(5):25-31 (In Russ.). https://doi.org/10.15372/SSMJ20180504
  10. Hokkanen VM, Chudinova OV, Popova SG. Causes of optical neuropathy in patients with respiratory tuberculosis. Sovremennyye tekhnologii v ofal’mologii. 2017;3:198-200 (In Russ.).
  11. Wang MY, Sadun AA. Drug-related mitochondrial optic neuropathies. J Neuroophthalmol. 2013;33(2):172-178.  https://doi.org/10.1097/WNO.0b013e3182901969
  12. Karuppannasamy D, Raghuram A, Sundar D. Linezolid-induced optic neuropathy. Indian J Ophthalmol. 2004;62(4):497-500.  https://doi.org/10.4103/0301-4738.118451
  13. Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Curr Opin Ophthalmol. 2017;28(6):545-551.  https://doi.org/10.1097/ICU.0000000000000416
  14. Nagra PK, Foroozan R, Savino PJ, Castillo I, Sergott RC. Amiodarone induced optic neuropathy. Br J Ophthalmol. 2003;87(4):420-422.  https://doi.org/10.1136/bjo.87.4.420
  15. Passman RS, Bennett CL, Purpura JM, Kapur R, Johnson LN, Raisch DW, Kapur R, Johnson LN, Raisch DW, West DP, Edwards BJ, Steven M, Belknap M, Fisher MJ, Samaras AT, Jones LGA, Tulas KE, McKoy JM. Amiodarone-Associated Optic Neuropathy: A Critical Review. Am J Med. 2012;125(5):447-453.  https://doi.org/10.1016/j.amjmed.2011.09.020
  16. Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol. 1984;19(4):178-186. 
  17. Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. Am J Ophthalmol. 1991;111(4):518-519.  https://doi.org/10.1016/s0002-9394(14)72398-0
  18. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998;42(4):360-366.  https://doi.org/10.1016/s0039-6257(97)00118-5
  19. Ingram DV. Ocular effects in long-term amiodarone therapy. Am Heart J. 1983;106(4):902-905.  https://doi.org/10.1016/0002-8703(83)90014-5
  20. Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. Doc Ophthalmol. 1993;83(4):323-329.  https://doi.org/10.1007/bf01204334
  21. Zrenner E, Hart W. Drug-induced and toxic disorders in neuro-ophthalmology. In: Schiefer, Wilheim and Hart. Clinical Neuro-Ophthalmology — A Practical Guide. Berlin: Springer; 2007.
  22. Gorkin L, Hvidsten K, Sobel R, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Intern J Clin Pract. 2006;60(4):500-503.  https://doi.org/10.1111/j.1368-5031.2006.00904.x
  23. Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol. 2011; 59(2):137-141.  https://doi.org/10.4103/0301-4738.77035
  24. Walsh F, Hoyt W. Neurotoxic substances: Methyl Alcohol. In: Rizo M., Barton J., eds. Walsh and Hoyt’s Clinical Neuro-ophthalmology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
  25. Fraunfelder FW, Sadun AA, Wood T. Update on ethambutol optic neuropathy. Expert Opin Drug. 2006;5(5):615-618.  https://doi.org/10.1517/14740338.5.5.615
  26. Fraunfelder FW, Pomeranz HD, Egan RA. Nonarteritic anterior ischemic opticneuropathy and sildenafil. Arch Ophthalmol. 2006;124:733-734. 
  27. Fintak D. Wills Eye Resident Case Series. Rev Ophthalmol. 2007.
  28. Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol. 1997;11(2):106-110.  https://doi.org/10.3341/kjo.1997.11.2.106
  29. Asayama T. Two cases of bitemporal hemianopsia due to ethambutol. Jpn J Clin Ophthalmol. 1969;23:1209-1212.
  30. Kedar S, Ghate D, Corbett JJ. Visual fields in neuro-ophthalmology. Indian J Ophthalmol. 2011;59(2):103-109.  https://doi.org/10.4103/0301-4738.77013
  31. Kokkada SB, Barthakur R, Natarajan M, Palaian S, Chhetri AK, Mishra P. Ocular side effects of antitubercular drugs — a focus on prevention, early detection and management. Kathmandu Univ Med J. 2005;3(4):438-441. 
  32. Kardon R, Morrisey MC, Lee AG. Abnormal Multifocal Electroretinogram (mfERG) in ethambutol toxicity. Semin Ophthalmol. 2006;21(4):215-222. 
  33. Kocabay G, Erelel M, Tutkun IT, Ecder T. Optic neuritis and bitemporalhemianopsia associated with isoniazid treatment inendstage renal failure. Int J Tuberc Lung Dis. 2006;10(12):1418-1419.
  34. Kulkarni HS, Keskar VS, Bavdekar SB, Gabhale Y. Bilateral optic neuritis due to isoniazid (INH). Indian Pediatr. 2010;47:533-535.  https://doi.org/10.1007/s13312-010-0083-5
  35. Azamfirei L, Copotoiu SM, Branzaniuc K, Szederjesi J, Copotoiu R, Berteanu C. Complete blindness after optic neuropathy induced by shortterm linezolid treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf. 2007;16(4):402-404.  https://doi.org/10.1002/pds.1320
  36. Joshi L, Taylor SR, Large O, Yacoub S, Lightman S. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia. Clin Infect Dis. 2009;48(7):73-74.  https://doi.org/10.1086/597298
  37. Samarakoon N, Harrisberg B, Ell J. Ciprofloxacin-induced toxic optic neuropathy. Clin Exp Ophthalmol. 2007;35:102-104.  https://doi.org/10.1111/j.1442-9071.2007.01427
  38. Vrabec TR, Sergott RC, Jaeger EA, Savino PJ, Bosley TM. Reversible visual loss in a patient receiving high-dose ciprofloxacin hydrochloride (Cipro). Ophthalmology. 1990;97(6):707-710.  https://doi.org/10.1016/s0161-6420(90)32518-6
  39. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumabin the treatment of uveitis. Ocul Immunol Inflamm. 2010;18(6):475-481.  https://doi.org/10.3109/09273948.2010.495814
  40. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22(5):134-140. 
  41. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattey D, Baddley JW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR. Initiation of anti-TNF therapy andthe risk of optic neuritis: from the Safety Assessment of Biologic ThE Rapy (SABER) study. Am J Ophthalmol. 2013;155(1):183-189.  https://doi.org/10.1016/j.ajo.2012.06.023
  42. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129(3): 819-826.  https://doi.org/10.1053/j.gastro.2005.06.022
  43. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46(7):1851-1856. https://doi.org/10.1002/art.10370
  44. Viestenz A, Viestenz A, Mardin CY. Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature. Ophthalmologe. 2003;100:402-405.  https://doi.org/10.1007/s00347-002-0745-3
  45. Best JL, Acheson JF. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication. Eye. 2005; 19(1):41-44.  https://doi.org/10.1038/sj.eye.6701405
  46. Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M, Dubus E, Craft CM, Ye W, Collins SD, Dulac O, Chiron C, Sahel JA, Picaud S. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65(1):98-107.  https://doi.org/10.1002/ana.21526
  47. Kazaryan AA, Obvintseva LV, Lebenkova OA, Barseghyan AS Amiodarone-induced optical neuropathy: clinical cases. Rossiyskiy oftal’mologicheskiy zhurnal. 2015;8(4):45-53 (In Russ.).
  48. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone optic-neuropathy. Am J Ophthalmol. 1999;127(5):610-612.  https://doi.org/10.1016/s0002-9394(99)00016-1
  49. Gittinger JWJ, Asdourian GK. Papillopathy caused by amiodarone. Arch Ophthalmol. 1987;105(3):349-351.  https://doi.org/10.1001/archopht.1987.01060030069028
  50. Purvin V, Kawasaki A, Borruat FX. Optic Neuropathy in Patients Using Amiodarone. Arch Ophthalmol. 2006;124(5):696-701.  https://doi.org/10.1001/archopht.124.5.696
  51. Castello DD, Teitelbaum BA, Tresley DJ. Visual changes secondary to initiation of amiodarone: A case report and review involving ocular management in cardiac polypharmacy. Optometry. 2002;73(2):113-121. 
  52. Speicher MA, Goldman MH, Chrousos GA. Amiodarone optic neuropathy without disc edema. J Neuroophthalmol. 2000;20(3):171-172.  https://doi.org/10.1097/00041327-200020030-00007
  53. Mindel JS, Anderson J, Hellkamp A. Absence of bilateral vision loss from amiodarone: a randomized trial. Am Heart J. 2007;154(1):837-842.  https://doi.org/10.1016/j.ahj.2007.02.010
  54. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14(1):38-44. 
  55. Hattenbauer MG, Leavitt JA, Hodge DO Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997; 123(1):103-107.  https://doi.org/10.1016/s0002-9394(14)70999-7
  56. Fasler K, Traber GL, Jaggi GP, Landau K. Amiodarone-associated Optic Neuropathy — A Clinical Criteria-based Diagnosis? Neuro-ophthalmology. 2018;42(1):2-10.  https://doi.org/10.1080/01658107.2017.1340961
  57. Reinharden DI, Azaravichen AP, Vashkelene II. Amiodaronekeratopathy. Kardiologiya. 2003;43(5):56-59 (In Russ.).
  58. Kerr NM, Danesh-Meyer HV. Phosphodiesterase inhibitors and the eye. Clin Exp Ophthalmol. 2009;37(5):514-523.  https://doi.org/10.1111/j.1442-9071.2009.02070.x
  59. Laties AM. Vision disorders and phosphodiesterase Type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009;32(1):1-18.  https://doi.org/10.2165/00002018-200932010-00001
  60. Felekis T, Asproudis I, Katsanos K, Tsianos EV. A case of nonarteritic anterior ischemic optic neuropathy of a male with family history of the disease after receiving sildenafil. Clin Ophthalmol. 2011;5:1443-1445. https://doi.org/10.2147/OPTH.S21243
  61. Hayreh SS. Pathogenesis of some controversial non-arteritic anterior ischemic optic neuropathy. In: Hayreh S.S. (ed.). Ischemic optic neuropathies. Berlin: Heidelberg: Springer-Verlag; 2011.
  62. Pomeranz H, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol. 2005;25(1):9-13.  https://doi.org/10.1097/00041327-200503000-00003
  63. Ezer N, Benedetti A, Darvish-Zargar M, Menzies D. Incidence ofethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013;17(4):447-455.  https://doi.org/10.5588/ijtld.11.0766
  64. Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007;91(7):895-897.  https://doi.org/10.1136/bjo.2006.113118
  65. Murphy MA, Murphy JF. Amiodarone and Optic Neuropathy: The Heart of the Matter. J Neuroophthalmol. 2005;25(3):232-236.  https://doi.org/10.1097/01.wno.0000177290.09649.38
  66. Almog Y, Goldstein M. Visual outcome in eyes with asymptomatic optic disc edema. J Neuroophthalmol. 2003;23(3):204-207.  https://doi.org/10.1097/00041327-200309000-00004
  67. Feiner LA, Younge BR, Kazmier FJ. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 1987;62:702-717. 
  68. Bereznikov AI, Filippenko NG. Features of the treatment of toxiclesions of the optic nerve. Nauchnyye vedomosti Belogorodskogo gosudarstvennogo universiteta. Seriya: Meditsina, farmatsiya. 2014;11-1(182):25-28. (In Russ.).
  69. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;21:127-141.  https://doi.org/10.2165/00002018-200831020-00003
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.